Latest News & Updates

Breaking News

7 hours ago
Vaibhavi M.

Zydus Launches Semaglutide Injection With Reusable Pen To Improve Diabetes Care Access, Patent Expiry Opens Door For Affordable GLP-1 Therapy

Glenmark Launches Affordable Semaglutide GLIPIQⓇ To Expand Diabetes Care Access In India, Sets New Cost Benchmark For GLP-1 Therapy With Flexible Dosing Options

Vaibhavi M.

Bristol Myers Squibb’s Opdivo Gains Dual US And EU Approvals In Hodgkin Lymphoma, Opdivo Combinations Deliver Strong Survival Benefits

Vaibhavi M.

Macau Grants First Asian Approval To ImmunityBio’s ANKTIVA For Bladder Cancer, Expands Global Reach As ANKTIVA Wins Regulatory Clearance

Vaibhavi M.

Novartis Strikes Up To $3B Deal To Acquire Next-Gen PI3Kα Breast Cancer Therapy, Expands Oncology Pipeline With Acquisition

Vaibhavi M.

Other trending news you may like to read

Zydus Launches Semaglutide Injection With Reusable Pen To Improve Diabetes Care Access, Patent Expiry Opens Door For Affordable GLP-1 Therapy

Zydus Lifesciences launches semaglutide injection under brands SEMAGLYN, MASHEMA, and ALTERME in India with a reusable multi-dose pen, priced at approximately ₹2,200 per month.

Vaibhavi M.

Glenmark Launches Affordable Semaglutide GLIPIQⓇ To Expand Diabetes Care Access In India, Sets New Cost Benchmark For GLP-1 Therapy With Flexible Dosing Options

Glenmark Pharmaceuticals launches GLIPIQ (semaglutide) in India for Type 2 diabetes after CDSCO approval, with weekly costs from ₹325 and a patient support program called Sankalp.

Vaibhavi M.

Bristol Myers Squibb’s Opdivo Gains Dual US And EU Approvals In Hodgkin Lymphoma, Opdivo Combinations Deliver Strong Survival Benefits

FDA and European Commission approve Bristol Myers Squibb's Opdivo (nivolumab) for classical Hodgkin lymphoma in separate combination regimens, backed by Phase III SWOG 1826 trial data.

Vaibhavi M.

Macau Grants First Asian Approval To ImmunityBio’s ANKTIVA For Bladder Cancer, Expands Global Reach As ANKTIVA Wins Regulatory Clearance

Macau's ISAF approves ImmunityBio's ANKTIVA (nogapendekin alfa inbakicept-pmln) combined with BCG for BCG-unresponsive NMIBC, marking ANKTIVA's first regulatory approval in Asia.

Vaibhavi M.